Literature DB >> 1293974

In vivo administration of propranolol decreases exaggerated amounts of serum TNF-alpha in patients with migraine without aura. Possible mechanism of action.

V Covelli1, I Munno, N M Pellegrino, M R Marinaro, A Gesario, F Massari, S Savastano, E Jirillo.   

Abstract

Patients with migraine without aura (MWA) display elevated amounts of Tumor Necrosis Factor (TNF)-alpha in their sera. In this study in 18 patients with MWA the in vivo effect of propranolol, a beta blocker agent, was evaluated with regard to the TNF serum levels before and after treatment. Results show that in 9 out 11 patients exaggerated serum concentrations of TNF reverted to normality after three months of therapy. Some hypotheses on the mechanisms of action of propranolol in terms of modulation of the immune response are formulated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1293974

Source DB:  PubMed          Journal:  Acta Neurol (Napoli)        ISSN: 0001-6276


  3 in total

1.  Tumor necrosis factor-alpha stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons.

Authors:  Elizabeth J Bowen; Thomas W Schmidt; Christina S Firm; Andrew F Russo; Paul L Durham
Journal:  J Neurochem       Date:  2005-11-08       Impact factor: 5.372

2.  The synergistic effects of ω-3 fatty acids and nano-curcumin supplementation on tumor necrosis factor (TNF)-α gene expression and serum level in migraine patients.

Authors:  Mina Abdolahi; Abbas Tafakhori; Mansoureh Togha; Ali Asghar Okhovat; Feridoun Siassi; Mohammad Reza Eshraghian; Mohsen Sedighiyan; Mona Djalali; Niyaz Mohammadzadeh Honarvar; Mahmoud Djalali
Journal:  Immunogenetics       Date:  2017-05-06       Impact factor: 2.846

3.  Tumor Necrosis Factor (TNF) -308G>A, Nitric Oxide Synthase 3 (NOS3) +894G>T Polymorphisms and Migraine Risk: A Meta-Analysis.

Authors:  Min Chen; Wenjing Tang; Lei Hou; Ruozhuo Liu; Zhao Dong; Xun Han; Xiaofei Zhang; Dongjun Wan; Shengyuan Yu
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.